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Bone marrow edema-like lesions change
in volume in the majority of patients
with osteoarthritis; associations
with clinical features
Abstract It has been suggested that
bone marrow edema-like (BME) le-
sions in the knee are associated with
progression of osteoarthritis (OA).
The purpose of our study in patients
with OAwas to evaluate prospectively
changes of BME lesions over 2 years
and their relationship with clinical
features. Magnetic resonance (MR)
images of the knee were obtained from
182 patients (20% male; aged 43–
76 years; mean age 59 years) who had
been diagnosed with familial symp-
tomatic OA at multiple joint sites. MR
images were made at baseline and at
2 years follow-up. BME lesions in
2 years were associated with clinical
features assessed by Western Ontario
and McMaster Universities Osteoar-
thritis (WOMAC) scores. A total of
327 BME lesions were recorded. Total
size of BME lesions changed in 90
patients (66%). Size of individual
lesions changed in 147 foci (45%):
new lesions appeared in 69 (21%),
existing lesions disappeared in 32
(10%), increased in size in 26 (8%)
and decreased in size in 20 (6%)
lesions. Increase or decrease of BME
lesions, over a 2-year time period, was
not associated with severity of
WOMAC scores. BME lesions fluc-
tuated in the majority of patients with
OA over a 2-year time period. These
changes were not associated with
severity of WOMAC scores at the
study end point.
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Introduction
Knee osteoarthritis (OA) is a chronic, progressive joint
disease, leading to pain and loss of function in a
considerable proportion of patients, with great impact and
consequences in the ageing population of the industrialized
world. Disease markers need to be identified in order to
predict and quantify progression. One possible marker in
OA is the so-called bone marrow edema-like (BME)
lesions [1].
Unfortunately, the role of BME in OA remains
controversial, as contradictory results have been reported.
BME detected with magnetic resonance (MR) imaging has
been associated with clinical symptoms in patients with
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between BME lesions and clinical symptoms [4–6].
Further, the role of BME as a marker for progression of
OA is open to discussion. In a study by Felson et al. [7],
BME was associated with progression of OA as assessed
by joint space narrowing on conventional radiographs. On
the other hand, in a study by Phan et al. [5], changes in
BME did not significantly change with progression of
disease assessed by Western Ontario and McMaster
Universities Osteoarthritis (WOMAC) scores.
Since these contradictory results regarding the associa-
tion between BME and clinical features have been
reported, the purpose of our study was to evaluate changes
in BME lesions over a 2-year period, and associate them
with clinical features.
Patients and methods
Patients
The present prospective study is part of the ongoing GARP
(Genetics, Osteoarthritis and Progression) study [8]. The
primary goal of the GARP study is the identification of
genetic susceptibility determinants to OA and disease
progression in middle-aged sibling pairs with OA at
multiple joint sites. MR image sets of the knee were
obtained in 182 patients at study entry and after 2 years [6].
Only one knee, the most symptomatic, was imaged per
patient. In the present, study 39% (71/182) of the patients
had symptomatic knee OA in their imaged knee, defined as
pain or stiffness on most days in the month prior to study
entry, and osteophytes on radiographs. As the purpose of
the MR study was to assess progression of OA, no images
were made of a knee that already had a maximum Kellgren
and Lawrence score of grade 4 [9].
Clinical assessment
Clinical data were assessed by WOMAC to assess pain,
stiffness and functional impairment of the imaged knee at
the 2-year time point, not at baseline [10].
MR acquisition
Knees were imaged using a transmit-receive four-channel
knee coil in a 1.5-T superconducting magnet (Philips
Medical Systems, Best, the Netherlands). Each examina-
tion consisted of: coronal proton density and T2-weighted
dual spin echo (SE) images (with repetition time (TR) of
2,200 ms; echo time (TE) of 20/80 ms; number of
excitations per data line (NEX) 2; 5 mm slice thickness;
0.5 mm intersection gap; 160 mm field of view (FOV);
256×205 acquisition matrix, 18 slices); sagittal proton
density and T2-weighted dual SE images (TR 2,200 ms;
TE 20/80 ms; NEX 2; 4 mm slice thickness; 0.4 mm
intersection gap; 160 mm (FOV); 256×205 acquisition
matrix, 20 slices); sagittal 3D T1-weighted spoiled gradient
echo (GE) frequency selective fat suppressed images (TR
46 ms; TE 2.5 ms; NEX 1; flip angle 40°; 3.0 mm slice
thickness; slice overlap 1.5 mm; no gap; 180 mm (FOV);
256 acquisition matrix, 80 slices); and axial proton density
and T2-weighted turbo spin echo (TSE) fat suppressed
images (TR 2,500 ms; TE 7.1/40 ms; NEX 2; 2 mm slice
thickness; no gap; 180 mm (FOV); 256 acquisition matrix,
62 slices). Total acquisition time (including the initial
survey sequence) was 30 min.
MR interpretation
All MR images were analyzed in known chronological
order by means of consensus between three experienced
readers, using a comprehensive score form [11]. During the
assessment, the readers were blinded to radiographic
results, patient symptoms and patient age. In cases of
disagreement between the readers the more conservative,
less severe score was recorded. BME or cysic lesions was
assigned to any one or more of the following anatomic
locations: the crista patellae, medial or lateral patellar
facets, the medial or lateral trochlear articular facets, the
medial or lateral femoral condyles, the medial or lateral
tibial plateaux.
BME lesions were defined as an ill-defined area of
increased signal intensity on T2-weighted images in the
subchondral bone, extending away from the articular
surface over a variable distance [12]. The lesions were
graded as follows: grade 0, absent; grade 1, minimal
(diameter <5 mm); grade 2, moderate (diameter 5 mm–
20 mm); grade 3, severe (diameter >20 mm). The
maximum two-dimensional diameter was measured to
grade the lesion. A total BME score of the knee was
calculated by adding all grades of each BME lesion in the
knee. Maximum possible knee score was 27 (grade 3 times
nine anatomic locations). In the total study a maximum of
1,638 BME lesions (182 patients times nine anatomic
locations) could be scored.
Subchondral cysts were defined as well-defined foci of
high signal intensity, with low signal intensity margins, on
T2-weighted images, in the bone underlying the joint
cartilage. Their greatest dimension was measured and they
were graded as follows: grade 0, absent; grade 1, minimal
(<3 mm); grade 2, moderate (3–5 mm); grade 3, severe
(>5 mm). A total score of the knee was calculated by
adding all grades of each cystic lesion in the knee.
Maximum possible knee score was 27 (grade 3 times nine
anatomic locations). In the total study a maximum of 1638
cystic lesions (182 patients times nine anatomic locations)
could be scored.
3074Statistical analysis
Odds ratios (ORs) with 99% confidence intervals (CIs)
were used to show any association between BME size
changes with cystic size changes.
The difference in WOMAC scores between patients
without BME lesions (group A) and patients with BME
lesions (group B: unchanged BME lesions over 2 years;
group C: increasing size of BME lesions over 2 years;
group D: decreasing size of BME lesions over 2 years) was
calculated by linear mixed models in SPSS for Windows,
version 12.0 (SPSS, Chicago, Ill.) with a random intercept
to adjust for the familial effect within sib pairs. Adjust-
ments were made for age, sex and body mass index (BMI).
Estimates of fixed effects were reported with 95% CIs.
Results
In total 182 patients were monitored over a period of 2 years
(Table1).Forty-six(25%)patientsdidnothaveBMElesions;
thus, 136 patients (75%) had oneor more BME lesions at any
time point. In 46 (34%) of patients, BME scores did not
fluctuate, whereas they changed in the other 90 (66%)
patients.ThetotalBMEscoreperindividualpatientincreased
in 54 (40%) patients. It decreased in 27 patients (20%), and
total BME score remained unchanged in nine (7%) patients.
Individual BME scores did change in this last group without
resulting in a change of the total BME score. A total of 327
BME lesions were detected from a possible total of 1,638
lesions (Table 2). One hundred and forty-seven (45%) BME
lesions changed: 69 new lesions appeared on the second MR
(21%), 26 (8%) increased, 20 (6%) decreased in size, and 32
(10%)werenolongervisibleonthesecondMRscan(Fig.1).
It was noted that more lesions appeared or increased than
decreased or disappeared.
One hundred (55%) patients had one or more cystic
lesions at any time. In 44 patients (44%), total cystic score
did not fluctuate over time, whereas in the other 56 patients
(56%) the total cystic score changed in size. In 36 of these
56 patients (64%) the cystic score increased, it decreased in
18 patients (32%), and the total cystic score remained
unchanged irrespective of changes on the level of
individual cysts in two patients (4%). A total of 222 cystic
lesions were detected from a possible total of 1,638 sites
(Table 2). Seventy cystic lesions (32%) changed: 32 new
cysts appeared on the second MR (46%), 14 (20%)
increased, six (8%) decreased in size, and 18 (26%) were
no longer visible on the second MR (Fig. 2).
Cystic and BME lesions were both present in the same
anatomic location (associated lesions) in 191 cases. A
change of BME lesions or cystic lesions was associated
with a change in size of an adjacent cystic or BME lesion
(OR: 6.2; 95% CI: 3.2–12.3). In 47 cases both BME
lesions and cystic lesions changed. When cystic and BME
lesions were both present in the same anatomic location,
size changes (increase or decrease) were in same direction
(OR: 37; 95% CI: 6–210) (Table 2).
One hundred and fifty-seven (86%) patients completed a
WOMAC questionnaire of the imaged knee at 2 years. The
WOMAC pain and function scores for patients without and
with BME lesions over 2 years are shown in Fig. 3a and b,
respectively. The mean WOMAC scores did not differ
between the different patient groups; even when BME
lesions completely disappeared, lower WOMAC scores
were not recorded. The mean difference in WOMAC pain
Table 2 Cystic and BME lesions per patient changing over 2 years in 182 patients (n=1,638)
BME lesions
No BME No change Increase Decrease Total
Cysts No cyst 1,280 77 38 21 1,416
No change 24 87 24 17 152
Increase 2 11 30 3 46
Decrease 5 5 3 11 24
Totals 1,311 180 95 52 1,638
Table 1 Patient characteristics (n=182)
At baseline
Age years, median (range) 59 (43–76)
Female sex, (%) 157 (80%)
Body mass index (kg/m
2), median (range) 25.7 (20.2–40.0)
Symptomatic knee OA, n (%)
a 71 (39%)
Kellgren & Lawrence Score 0/1/2/3/4, No. 59/53/60/10/0
Over 2 years
Bone marrow edema-like lesions, n (%)
b 128 (70%)
Grade 0/1/2/3
c 54/56/62/10
Cysts, n (%)
b 100 (55%)
Grade 0/1/2/3
c 82/60/37/3
At 2 years
WOMAC Pain scores, median (range)
d 13 (0–99)
WOMAC Stiffness scores, median (range)
d 18 (0–99)
WOMAC Function scores, median (range)
d 14 (0–98)
aDefined as pain or stiffness on most days of the month prior to
study entry, in combination with osteophytes on radiographs
bDuring 2 years
cMaximal grade per patient
dn=157
3075Fig. 1 a–d Axial T2-weighted
turbo spin echo fat suppressed
images. Increase (a at baseline,
b after two years) in size of bone
marrow edema-like lesions over
2 years at the crista patella
(arrow) and at the medial fem-
oral condyle (arrowhead). De-
crease (c at baseline, d after two
years) in size of bone marrow
edema-like lesions over 2 years
at the crista and medial part of
the patella (open arrowhead)
Fig. 2a, b Axial T2-weighted
turbo spin echo fat suppressed
images. Disappearing cyst at the
lateral femoral condyle (arrow).
a At baseline, b after 2 years
3076scores between patients with unchanged BME lesions, with
increasing BME lesions and with decreasing BME lesions
compared with patients without BME lesions were 2 (95%
CI-8 to 12), 2 (95% CI-8 to 11) and 1 (95% CI-11 to 12)
respectively (Fig. 3a). The mean difference in WOMAC
function scores between patients with unchanged BME
lesions, with increasing BME lesions and with decreasing
BME lesions compared to patients without BME lesions
were −2 (95CI-12 to 8), −4 (95CI-13 to 6) and −4 (95CI-15
to 8) respectively (Fig. 3b).
Discussion
Themajority (75%) of patients with familial OA at multiple
sites have BME lesions visualized when two sequential
MR scans are made with a 2-year time interval. In the
majority (66%) of these patients with BME lesions, the
total size of BME changed over this 2-year time period.
Our study also demonstrates that cysts and BME fluctua-
tions are associated. However, no association existed
between changes in BME lesions and severity of
WOMAC scores after 2 years.
The finding, that BME lesions fluctuate in 66% of the
patients, indicates that BME is part of a dynamic process in
OA. BME is not a constant finding, as opposed to hyaline
cartilage loss for example. Thus, it is important to realize
that the finding of BME lesions in patients with OA
represents only a single snapshot in time. The variability of
BME lesions has been noted before [5]. It is also interesting
and important to note that 10% of BME lesions disappear
completely. This is particularly noteworthy if BME is to be
used as an inclusion criterion, outcome parameter or
surrogate endpoint in drug trials or clinical outcome studies.
The second finding of the present study is that when
cystic lesions and BME lesions are in close proximity; the
direction in which they change is identical. This is an
interesting finding as the role of cysts in OA is unclear.
Their exact pathophysiology is uncertain, as is their
prognostic significance. A recent study by Carrino et al.
[13] also showed a change in cyst size was accompanied by
a change in oedema-like signal size. That study also
showed subchondral cysts developing in pre-existing
regions of subchondral bone marrow oedema-like signal.
The third finding is that changes in BME lesions did not
correlate with severity of WOMAC scores. Patients in
whom BME increased did not have a higher WOMAC
score than patients with a decrease in BME size. Even
when BME completely disappeared, lower WOMAC
scores were not recorded. Previous work has demonstrated
that pain, as assessed by WOMAC scores, was not related
significantly to changes in BME lesions [5]. However, in
the studies by Felson et al. [2, 7], BME was associated with
progressive radiographic knee OA and pain. Cross
sectional associations between BME lesions and clinical
findings remain controversial [2–6]. Hence, a lack of
clarity about the relationship between changes in BME
lesions and WOMAC scores is not surprising. Phan et al.
[5] have suggested that the complexity of pain physiology
and the difficulty of pain evaluation may explain these
findings, as well as the fact that patients experience pain
differently. Another important factor might be the stage of
OA in the patients being studied. For instance, pain might
be associated with BME lesions in a more developed stage
of the disease and less so earlier on. Knee OA studied in the
population by Felson [2] was more advanced than the
GARP population [8]. Also Felson’s population consisted
of patients with knee OA only, whereas the GARP
Fig. 3 Association between WOMAC pain (a) or function (b)
scores and bone marrow edema-like lesions. Group A: patients with
no bone marrow edema-like lesions; Group B: patients in whom
bone marrow edema-like lesions did not change over 2 years; Group
C: patients in whom bone marrow edema-like lesions increased in
size over 2 years; Group D: patients in whom bone marrow edema-
like lesions decreased in size over 2 years. Box plots show the
median, interquartile range, minimum and maximum values
3077population is focused on patients with familial OA at
multiple sites. A considerable proportion of patients in the
present study did not have symptomatic radiographic knee
OA in the imaged knee, and consequently average
WOMAC scores in the present population were low
(Table 1). Nevertheless, associations between BME lesions
and clinical findings are controversial and BME lesions
may be excluded ultimately as a factor in pain sensation.
The present study has a number of limitations. Firstly,
not all patients with a complete MRI follow-up completed
the WOMAC signal knee. Secondly, the inclusion of
patients who were first-degree relatives may have intro-
duced an artefact. However, linear regression analysis, with
robust standard errors that clustered on pairs, excluded this
possibility. Thirdly, although referred pain from the hip
may have been a confounder, hip OA occurred in only 7%
of the patients and was not thought a contributory factor.
Fourthly, 2 years of follow-up may be too short for an early
OA population. However, we did find a considerable
change in size of both cystic and BME lesions. Finally, the
term BME used in this article probably should be described
more properly as “ill defined signal intensity abnormal-
ities”, as the so-called BME pattern in OA knees represents
on histological examination nonspecific abnormalities such
as bone marrow necrosis, bone marrow fibrosis, trabecular
abnormalities and only a small amount of bone marrow
oedema [1]. Nevertheless, the term BME is a commonly
accepted identity and widely used in the OA literature [2].
In conclusion, BME lesions are shown to be a variable
parameter when followed over time in patients with knee
OA and are not predictive of pain.
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